About Sequenta
Sequenta is a Healthcare company based in San Francisco (United States) founded in 2008 by Malek Faham and Thomas Willis, and was acquired by Adaptive Biotechnologies in January 2015. Immuno-sequencing products are developed for disease diagnostics and treatment. Sequenta has raised $43.46 million across 5 funding rounds from investors including Adaptive Biotechnologies, Celgene and Foresite Capital. The company was acqui-hired. Sequenta offers products and services including clonoSEQ, Adaptive Immunosequencing, and TCR Therapeutics. Its focus areas include Life Sciences, Genomics, Applied Genomics and Clinical Genomics. Its legal entity is Sequenta Inc. Its competitors include Guardant Health, Natera and Foundation Medicine; 3 of its 3 listed competitors have raised funding.
Company details
Sequenta was founded in 2008 in San Francisco, United States, within the biotechnology sector. Immuno-sequencing technologies are researched and developed for applications in diagnosing and treating cancer, autoimmune disorders, and infectious diseases. A primary diagnostic test was produced to assess minimal residual disease in hematological cancers. Operations centered on these tools until acquisition by Adaptive Biotechnologies in January 2015 for an undisclosed sum.
- Headquarters San Francisco, United States
- Founders Malek Faham, Thomas Willis
- Stage Acquired
- SectorsHealthcare
- Phone•••• ••••
- Website sequenta.com
- Social LinkedIn X Facebook Instagram YouTube
- Acquired by Adaptive Biotechnologies (Jan 2015)
- Legal Name Sequenta Inc
- Total Equity Funding$43.46M (USD)
in 5 rounds
- InvestorsAdaptive Biotechnologies
& 4 more
- Acquired byAdaptive Biotechnologies
(Jan 2015)
Products & Services of Sequenta
Sequenta offers a comprehensive portfolio of products and services, including clonoSEQ, Adaptive Immunosequencing, and TCR Therapeutics.
NGS-based test for assessing minimal residual disease in trials
Platform for immune receptor data analysis in drug development
Tools for T-cell receptor-based antibody therapies
Apps and channels of Sequenta
its YouTube channel Adaptive Biotechnologies has 677 subscribers.
Funding Insights of Sequenta
Sequenta has successfully raised a total of $43.46M across 5 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $43.46M
- Total Rounds 5
- First Round $2M
(Jul 2009)
- Investors Count 4
All 5 funding rounds of Sequenta with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2014 | Series D | – | – | ||
| Jul 2013 | $20M | Series C | – | – | |
| Feb 2012 | $8.46M | Series B | – | – | – |
| Nov 2010 | $13M | Series B | – | Index Ventures | |
| Jul 2009 | $2M | Series A | – | – |
5 investors in total: 5 institutional.
Investors in Sequenta
Sequenta has secured backing from 5 investors, including institutional and venture fund investors. Prominent investors backing the company include Adaptive Biotechnologies, Celgene and Foresite Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Multi-stage investment firm invests in healthcare and life sciences companies | foresitecapital.com | New York, United States | ||
Venture capital investments are managed in technology and healthcare sectors by this firm. | mdv.com | |||
Venture capital investments in technology startups and entrepreneurs. | indexventures.com | |||
Therapies for cancer and inflammatory diseases are developed. | 1986 | celgene.com | Summit, United States | |
Clinical diagnostics and drug discovery for immune diseases are provided. | 2009 | adaptivebiotech.com | Seattle, United States |
Investor details for Sequenta
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Sequenta
2 people are tracked at Sequenta (2 in leadership).
| Name | Role | Group |
|---|---|---|
Malek Faham | Co-Founder | Leadership |
Thomas Willis | Co-Founder | Leadership |
Complete people profiles for Sequenta
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Sequenta
4 dated milestones of Sequenta across 7 years, from founding to its latest funding, stage changes and deals.
- Founded Sequenta is founded.
- Funding First funding round of $2.0M.
- Funding Latest funding round, Series D,.
- Exit Acquired by Adaptive Biotechnologies.
Competitors of Sequenta
Sequenta has 3 listed competitors in our database, 3 of them funded. They include Guardant Health, Natera and Foundation Medicine.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| guardanthealth.com | 2012 | Redwood, United States | $557.5M | 1,351 | Digital sequencing technology for cancer detection is developed. | |
| natera.com | 2004 | Redwood, United States | $152.1M | 3,293 | Developer of cell-free DNA testing for oncology, women’s health, and organ health | |
| foundationmedicine.com | 2010 | Cambridge, United States | $96.5M | 1,707 | Genomics-based diagnostic tests for cancer are provided. |
Detailed competitors of Sequenta
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Sequenta (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Sequenta
Complete news archive for Sequenta
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Sequenta
Sequenta was founded in 2008 and raised its 1st funding round 1 year after it was founded.
Sequenta is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Sequenta is a funded company, having raised a total of $43.46M across 5 funding rounds to date. The company's 1st funding round was a Series A of $2M, raised on Jul 2009.
Sequenta was founded in 2008 in San Francisco, United States, within the biotechnology sector. Immuno-sequencing technologies are researched and developed for applications in diagnosing and treating cancer, autoimmune disorders, and infectious diseases. A primary diagnostic test was produced to assess minimal residual disease in hematological cancers. Operations centered on these tools until acquisition by Adaptive Biotechnologies in January 2015 for an undisclosed sum.
Sequenta's top competitors include Guardant Health, Foundation Medicine and Natera.
Sequenta offers clonoSEQ, Adaptive Immunosequencing, and TCR Therapeutics.
Sequenta has 5 investors. Key investors include Adaptive Biotechnologies, Celgene, Foresite Capital, Mohr Davidow Ventures, and Index Ventures.
Sequenta operates through Sequenta Inc.
Yes. Sequenta was acquired by Adaptive Biotechnologies in January 2015.